Cardiac Amyloidosis
Cardiac amyloidosis is a rare condition where abnormal protein deposits, known as amyloids, accumulate in the heart tissue, leading to heart dysfunction and symptoms such as shortness of breath, fatigue, and swelling in the legs.
Cardiac Amyloidosis: PET Imaging with Vizamyl®
We are studying a new imaging tracer to see how effectively it detects amyloid deposits in the hearts of patients with cardiac amyloidosis. This research may help improve diagnosis and understanding of the disease.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have known ischemic heart disease (a type of heart disease caused by narrowed arteries)?
- Are you currently pregnant or breastfeeding?
- Do you have severe liver disease (like cirrhosis or very high liver enzyme levels)?
- Do you have severe kidney disease (with kidney function below 30 mL/min)?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Fondazione Toscana Gabriele Monasterio
U.O.C. Medicina Nucleare
Pisa, Italy
Sponsor: Fondazione Toscana Gabriele Monasterio
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.